

Aztreonam/avibactam activity against a large collection
Enterobacterales (CRE) collected in hospitals from Euro
(2019–21)

JAC-Antimicrobial Resistance

5,

DOI: [10.1093/jacamr/dlad032](https://doi.org/10.1093/jacamr/dlad032)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Characterization of Carbapenemase- and ESBL-Producing Gram-Negative Bacilli Isolated from Patients with Urinary Tract and Bloodstream Infections. <i>Antibiotics</i> , 2023, 12, 1386.	3.7	1
2	In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo- β -Lactamase-Producing Gram-Negative Bacteria. <i>Antibiotics</i> , 2023, 12, 1493.	3.7	0
3	In vitro activity of aztreonam+avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019+2021. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2023, 42, 1135-1143.	2.9	3
4	Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 0, , .	1.7	0
5	Clinical Features and Outcomes of Infections Caused by Metallo- β -Lactamase+Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	0
6	Reviewing novel treatment options for carbapenem-resistant <i>Enterobacterales</i> . <i>Expert Review of Anti-Infective Therapy</i> , 2024, 22, 71-85.	4.4	0
7	Improved synthesis and evaluation of preclinical pharmacodynamic parameters of a new monocyclic β -lactam DPI-2016. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2024, 99, 129615.	2.2	0
8	Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation. <i>European Journal of Clinical Pharmacology</i> , 2024, 80, 529-543.	1.9	0
9	Carbapenem-Resistant Enterobacteriaceae in Urinary Tract Infections: From Biological Insights to Emerging Therapeutic Alternatives. <i>Medicina (Lithuania)</i> , 2024, 60, 214.	2.0	0
10	Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020+2022). <i>International Journal of Antimicrobial Agents</i> , 2024, 63, 107113.	2.5	0